Welcome to our dedicated page for Clene SEC filings (Ticker: CLNNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clene's regulatory disclosures and financial reporting.
Clene Inc. files a preliminary prospectus supplement under its Form S-3 shelf to offer shares of common stock (Nasdaq: CLNN), with aggregate shelf capacity of $160,000,000. The supplement does not state the number of shares or the public offering price per share; delivery and certain dates are left blank in this draft. The prospectus supplement describes use of proceeds for general corporate purposes, including funding clinical development of CNM-Au8, manufacturing and regulatory activities, and early-stage R&D.
The company reported 11,778,307 shares outstanding as of April 30, 2026. Financial context includes a loss from operations of $23.1M and cash and cash equivalents of $5.2M as of December 31, 2025, and the filing discloses substantial doubt about going concern and plans to seek additional financing.
Clene Inc. files a preliminary prospectus supplement under its Form S-3 shelf to offer shares of common stock (Nasdaq: CLNN), with aggregate shelf capacity of $160,000,000. The supplement does not state the number of shares or the public offering price per share; delivery and certain dates are left blank in this draft. The prospectus supplement describes use of proceeds for general corporate purposes, including funding clinical development of CNM-Au8, manufacturing and regulatory activities, and early-stage R&D.
The company reported 11,778,307 shares outstanding as of April 30, 2026. Financial context includes a loss from operations of $23.1M and cash and cash equivalents of $5.2M as of December 31, 2025, and the filing discloses substantial doubt about going concern and plans to seek additional financing.
Symbiosis II LLC reports multiple open-market sales of Common stock of CLNN recorded on Form 144. The filing lists numerous cash transactions from 01/28/2026 through 05/04/2026, including lots such as 67,991 shares on 03/31/2026 and 31,624 shares on 05/04/2026.
Symbiosis II LLC reports multiple open-market sales of Common stock of CLNN recorded on Form 144. The filing lists numerous cash transactions from 01/28/2026 through 05/04/2026, including lots such as 67,991 shares on 03/31/2026 and 31,624 shares on 05/04/2026.
Clene Inc. announced that after a constructive Type C meeting, the FDA stated its proposed data "may be capable of supporting" an accelerated approval New Drug Application (NDA) for ALS drug candidate CNM-Au8, based on neurofilament light (NfL) biomarker data.
The FDA acknowledged that NfL could potentially serve as a reasonably likely surrogate endpoint for accelerated approval under Subpart H. Clene intends to submit the NDA in the third quarter of 2026, supported by Phase 2 HEALEY ALS Platform and RESCUE-ALS trials and an NIH-sponsored Expanded Access Protocol, and plans a Phase 3 confirmatory study starting in the first quarter of 2027.
Clene Inc. announced that after a constructive Type C meeting, the FDA stated its proposed data "may be capable of supporting" an accelerated approval New Drug Application (NDA) for ALS drug candidate CNM-Au8, based on neurofilament light (NfL) biomarker data.
The FDA acknowledged that NfL could potentially serve as a reasonably likely surrogate endpoint for accelerated approval under Subpart H. Clene intends to submit the NDA in the third quarter of 2026, supported by Phase 2 HEALEY ALS Platform and RESCUE-ALS trials and an NIH-sponsored Expanded Access Protocol, and plans a Phase 3 confirmatory study starting in the first quarter of 2027.
Clene Inc. ten percent owner associated entity SymBiosis II, LLC sold 19,497 shares of Common Stock in open-market transactions. The sales occurred over three days at prices of $5.63, $5.90, and $6.08 per share. After these indirect sales, 277,569 shares of Clene Common Stock remain held through SymBiosis II, LLC.
Clene Inc. ten percent owner associated entity SymBiosis II, LLC sold 19,497 shares of Common Stock in open-market transactions. The sales occurred over three days at prices of $5.63, $5.90, and $6.08 per share. After these indirect sales, 277,569 shares of Clene Common Stock remain held through SymBiosis II, LLC.
Symbiosis II LLC reported multiple open-market sales of Common Stock under Rule 144. The filing lists repeated dispositions between 01/28/2026 and 04/21/2026, including large blocks such as 67,991 shares on 03/31/2026 and 61,345 shares on 04/21/2026. The transactions were reported as cash open-market sales.
Symbiosis II LLC reported multiple open-market sales of Common Stock under Rule 144. The filing lists repeated dispositions between 01/28/2026 and 04/21/2026, including large blocks such as 67,991 shares on 03/31/2026 and 61,345 shares on 04/21/2026. The transactions were reported as cash open-market sales.
Clene Inc. insider associated entity sells shares in two open-market transactions. An entity linked to ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold 4,318 shares of Clene common stock at $6.12 per share on April 20, 2026, followed by 61,345 shares at $6.14 per share on April 21, 2026. After the April 21 sale, the filing reports 297,066 Clene shares indirectly held by this entity.
Clene Inc. insider associated entity sells shares in two open-market transactions. An entity linked to ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold 4,318 shares of Clene common stock at $6.12 per share on April 20, 2026, followed by 61,345 shares at $6.14 per share on April 21, 2026. After the April 21 sale, the filing reports 297,066 Clene shares indirectly held by this entity.
Clene Inc. ten percent owner Ugwumba Chidozie, through SymBiosis II, LLC, reported open-market sales of Clene common stock over three days. SymBiosis II, LLC sold 6,374 shares at $6.48 on April 15, 7,748 shares at $6.40 on April 16, and 25,040 shares at $6.43 on April 17, leaving 362,729 shares of indirect ownership after the latest transaction.
Clene Inc. ten percent owner Ugwumba Chidozie, through SymBiosis II, LLC, reported open-market sales of Clene common stock over three days. SymBiosis II, LLC sold 6,374 shares at $6.48 on April 15, 7,748 shares at $6.40 on April 16, and 25,040 shares at $6.43 on April 17, leaving 362,729 shares of indirect ownership after the latest transaction.
CLNN filed a Form 144 notice reporting proposed sales of Common Stock, listing an entry of 401,891 shares under “Securities To Be Sold” (dated 09/30/2024) and multiple completed open-market sales by Symbiosis II LLC with trade dates and per-trade share counts and proceeds in 2026. The filing lists open-market purchase / resale activity and indicates cash transactions.
CLNN filed a Form 144 notice reporting proposed sales of Common Stock, listing an entry of 401,891 shares under “Securities To Be Sold” (dated 09/30/2024) and multiple completed open-market sales by Symbiosis II LLC with trade dates and per-trade share counts and proceeds in 2026. The filing lists open-market purchase / resale activity and indicates cash transactions.
Clene Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 21, 2026, in Salt Lake City. Holders of common stock at the March 25, 2026 record date can vote online, by phone, mail, or in person, with one vote per share.
Stockholders will elect three Class III directors to terms ending in 2029, ratify Deloitte as independent auditor for 2026, and cast an advisory vote on executive pay. A key item seeks to amend the Amended 2020 Stock Plan to add 1,000,000 shares, raising the share reserve from 3,220,000 to 4,220,000.
As of March 25, 2026, Clene had 11,778,307 common shares outstanding, 3,006,484 options outstanding under the plan, and 197,177 shares remaining available for grants. The company discloses a three-year average equity burn rate of 9.99% and estimates fully‑diluted overhang of 22.0%, which would rise to 26.8% if the amendment is approved.
Clene Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 21, 2026, in Salt Lake City. Holders of common stock at the March 25, 2026 record date can vote online, by phone, mail, or in person, with one vote per share.
Stockholders will elect three Class III directors to terms ending in 2029, ratify Deloitte as independent auditor for 2026, and cast an advisory vote on executive pay. A key item seeks to amend the Amended 2020 Stock Plan to add 1,000,000 shares, raising the share reserve from 3,220,000 to 4,220,000.
As of March 25, 2026, Clene had 11,778,307 common shares outstanding, 3,006,484 options outstanding under the plan, and 197,177 shares remaining available for grants. The company discloses a three-year average equity burn rate of 9.99% and estimates fully‑diluted overhang of 22.0%, which would rise to 26.8% if the amendment is approved.
Clene Inc. ten percent owner associated entity sells shares. An entity linked to Ugwumba Chidozie, SymBiosis II, LLC, completed an open-market sale of 4,278 shares of Clene Inc. common stock at $4.97 per share. After this transaction, the entity still holds 426,816 shares indirectly.
Clene Inc. ten percent owner associated entity sells shares. An entity linked to Ugwumba Chidozie, SymBiosis II, LLC, completed an open-market sale of 4,278 shares of Clene Inc. common stock at $4.97 per share. After this transaction, the entity still holds 426,816 shares indirectly.